CochLear Operating Income 2023-2024 | CHEOY
CochLear annual/quarterly operating income history and growth rate from 2023 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- CochLear operating income for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- CochLear operating income for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.
- CochLear annual operating income for 2024 was $0.312B, a 18.8% increase from 2023.
- CochLear annual operating income for 2023 was $0.262B, a 9.64% decline from 2022.
- CochLear annual operating income for 2022 was $0.29B, a 74.83% decline from 2021.
| CochLear Annual Operating Income (Millions of US $) |
|
|---|---|
| 2024 | $312 |
| 2023 | $262 |
| 2022 | $290 |
| 2021 | $1,153 |
| 2020 | $887 |
| 2019 | $1,020 |
| 2018 | $1,057 |
| 2017 | $945 |
| 2016 | $824 |
| CochLear Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2024-12-31 | |
| 2024-06-30 | |
| 2023-12-31 | |
| 2023-06-30 | |
| 2022-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $12.847B | $1.488B |
| Cochlear Limited provides implantable hearing solutions principally in the Americas, Europe, the Middle East, Africa and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories and Baha bone conduction implants. Cochlear Limited is based in Sydney, Australia. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $143.621B | 26.94 |
| CVS Health (CVS) | United States | $84.680B | 10.52 |
| Elevance Health (ELV) | United States | $78.955B | 10.19 |
| Cencora (COR) | United States | $57.765B | 20.10 |
| DiDi Global (DIDIY) | China | $23.297B | 24.75 |
| Natera (NTRA) | United States | $21.640B | 0.00 |
| Labcorp Holdings (LH) | United States | $21.549B | 17.48 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.690B | 0.00 |
| Solventum (SOLV) | United States | $12.990B | 13.75 |
| ICON (ICLR) | Ireland | $12.241B | 11.38 |
| Revvity (RVTY) | United States | $11.865B | 20.42 |
| Viatris (VTRS) | United States | $10.868B | 3.73 |
| Avantor (AVTR) | United States | $9.370B | 13.61 |
| Medpace Holdings (MEDP) | United States | $9.269B | 24.62 |
| HealthEquity (HQY) | United States | $8.917B | 39.06 |
| Sonic Healthcare (SKHHY) | Australia | $8.417B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.779B | 15.24 |
| Caris Life Sciences,�Inc (CAI) | United States | $6.688B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.952B | 29.17 |
| BrightSpring Health Services (BTSG) | United States | $3.769B | 34.58 |
| Sotera Health (SHC) | United States | $3.290B | 18.69 |
| Surgery Partners (SGRY) | United States | $2.853B | 37.10 |
| Alignment Healthcare (ALHC) | United States | $2.712B | 0.00 |
| Concentras Parent (CON) | United States | $2.615B | 15.11 |
| Organon (OGN) | United States | $2.587B | 2.75 |
| GeneDx Holdings (WGS) | United States | $2.432B | 93.65 |
| Progyny (PGNY) | United States | $2.080B | 45.79 |
| PACS (PACS) | United States | $1.972B | 0.00 |
| Ardent Health (ARDT) | United States | $1.970B | 8.40 |
| Premier (PINC) | United States | $1.805B | 13.70 |
| GoodRx Holdings (GDRX) | United States | $1.729B | 34.57 |
| Teladoc Health (TDOC) | United States | $1.493B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.271B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.159B | 8.82 |
| CareDx (CDNA) | United States | $1.072B | 16.74 |
| Agilon Health (AGL) | United States | $0.989B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.970B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.846B | 7.92 |
| Nutex Health (NUTX) | United States | $0.766B | 11.59 |
| QDM (QDMI) | Hong Kong, SAR China | $0.729B | 0.00 |
| Embecta (EMBC) | United States | $0.610B | 4.11 |
| InnovAge Holding (INNV) | United States | $0.574B | 0.00 |
| LifeMD (LFMD) | United States | $0.544B | 0.00 |
| SBC Medicals (SBC) | United States | $0.504B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.468B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.465B | 10.47 |
| Omada Health (OMDA) | $0.450B | 0.00 | |
| So-Young (SY) | China | $0.423B | 0.00 |
| Enhabit (EHAB) | United States | $0.370B | 30.42 |
| Performant Healthcare (PHLT) | United States | $0.333B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.324B | 0.00 |
| Beauty Health (SKIN) | United States | $0.265B | 0.00 |
| Oncology Institute (TOI) | United States | $0.223B | 0.00 |
| DocGo (DCGO) | United States | $0.158B | 25.83 |
| Pheton Holdings (PTHL) | China | $0.128B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.102B | 0.00 |
| KindlyMD (NAKA) | United States | $0.078B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.067B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.062B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| ModivCare (MODV) | United States | $0.055B | 0.00 |
| Biodesix (BDSX) | United States | $0.043B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.037B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.034B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.026B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.012B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.011B | 0.00 | |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |